|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021)显示文摘Background:Breast cancer with low-positive human epidermal growth factor receptor 2(HER2)expression has triggered further refinement of evaluation criteria for HER2 expression.We studied the clinicopathological features of early-stage breast cancer with low-positive HER2 expression in China and analyzed prognostic factors.Methods:Clinical and pathological data and prognostic information of patients with early-stage breast cancer with low-positive HER2 expression treated by the member units of the Chinese Society of Breast Surgery and Chinese Society of Surgery of Chinese Medical Association,from January 2015 to December 2016 were collected.The prognostic factors of these patients were analyzed.Results:Twenty-nine hospitals provided valid cases.From 2015 to 2016,a total of 25,096 cases of early-stage breast cancer were treated,7642(30.5%)of which had low-positive HER2 expression and were included in the study.After ineligible cases were excluded,6486 patients were included in the study.The median follow-up time was 57 months(4-76 months).The disease-free survival rate was 92.1%at 5 years,and the overall survival rate was 97.4%at 5 years.At the follow-up,506(7.8%)cases of metastasis and 167(2.6%)deaths were noted.Multivariate Cox regression analysis showed that tumor stage,lymphvascular invasion,and the Ki67 index were related to recurrence and metastasis(P<0.05).The recurrence risk prediction model was established using a machine learning model and showed that the area under the receiving operator characteristic curve was 0.815(95%confidence interval:0.750-0.880).Conclusions:Early-stage breast cancer patients with low-positive HER2 expression account for 30.5%of all patients.Tumor stage,lymphvascular invasion,and the Ki67 index are factors affecting prognosis.The recurrence prediction model for breast cancer with low-positive HER2 expression based on a machine learning model had a good clinical reference value for predicting the recurrence risk at 5 years.Trial registration:ChiCTR.org.cn,ChiCTR2100046766. | Ling Xin Qian Wu Chongming Zhan Hongyan Qin Hongyu Xiang Ling Xu Jingming Ye Xuening Duan Yinhua Liu Chinese Society of Breast Surgery(CSBrS) Chinese Society of Surgery of Chinese Medical Association | 2022 | Chinese Medical Journal2022，，6： | 9 |
| 2 | A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer(AJCC)cancer staging system for luminal A breast cancer显示文摘Objective: We retrospectively analyzed the clinical prognostic value of the 8th edition of the American Joint Committee on Cancer(AJCC) staging system for luminal A breast cancer.Methods: Using both the anatomic and prognostic staging in the 8th edition of AJCC cancer staging system, we restaged patients with luminal A breast cancer treated at the Breast Disease Center, Peking University First Hospital from 2008 to 2014. Follow-up data including 5-year disease free survival(DFS), overall survival(OS) and other clinic-pathological data were collected to analyze the differences between the two staging subgroups.Results: This study included 421 patients with luminal A breast cancer(median follow-up, 61 months). The 5-year DFS and OS rates were 98.3% and 99.3%, respectively. Significant differences in 5-year DFS but not OS were observed between different anatomic disease stages. Significant differences were observed in both 5-year DFS and OS between different prognostic stages. Application of the prognostic staging system resulted in assignment of 175 of 421 patients(41.6%) to a different group compared to their original anatomic stages. In total, 102 of 103 patients with anatomic stage IIA changed to prognostic stage IB, and 24 of 52 patients with anatomic stage IIB changed to prognostic stage IB, while 1 changed to prognostic stage IIIB. Twenty-two of 33 patients with anatomic stage IIIA were down-staged to IIA when staged by prognostic staging system, and the other 11 patients were down-staged to IIB. Two patients with anatomic stage IIIB were down-staged to IIIA. Among seven patients with anatomic stage IIIC cancer, two were down-staged to IIIA and four were down-staged to stage IIIB.Conclusions: The 8th edition of AJCC prognostic staging system is an important supplement to the breast cancer staging system. More clinical trials are needed to prove its ability to guide selection of proper systemic therapy and predict prognosis of breast cancer. | jingming ye wenjun wang ling xu xuening duan yuanjia cheng ling xin hong zhang shuang zhang ting li yinhua liu | 2017 | Chinese Journal of Cancer Research2017，29，4： | 8 |
| 3 | The efficacy of a voice training program:a case-control study in China显示文摘 | Jingming Duan Li Zhu Yan Yan | 2010 | Eur Arch Otorhinolaryngol2010，267，1： | 1 |
| 4 | Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy显示文摘There is a lack of investigation into the biological characteristics and preoperative systemic therapy(PST)for occult breast cancer(OBC).For this study,departmental records in Breast Disease Center of Peking University First Hospital from January 2008 to December 2015 were retrospectively reviewed to identify cases of OBC.Eleven cases were included,and all patients were female,with a median age of 56(range:29–75)years.The sensitivity of magnetic resonance imaging(MRI)was 100%,and the false positive rate was 33.3%.Based on histologic analysis of the axillary node,9(81.8%)cases were grade 3,and 2(18.2%)cases were grade 2;4(36.4%)cases were≥10%estrogen receptor(ER)positive and 6(54.5%)human epidermal growth receptor 2(HER2)positive.Nine cases(81.8%)exhibited over 30%Ki67 expression.PST was performed in 5 of the 11 cases.The lymph node response rate was 100%(5/5),but no complete remission was achieved.In conclusion,aggressive subtypes were predominant among the included cases,and PST should be considered for OBC treatment options. | Ling Xu Fang Li Yinhua Liu Xuening Duan Jingming Ye Yuanjia Cheng Ling Xin | 2017 | Chinese Journal of Cancer Research2017，29，4： | 1 |
| 5 | The efficacy of a voice training program: a case–control study in China显示文摘 | Jingming Duan Li Zhu Yan Yan Tao Pan Peiquan Lu Furong Ma | 2010 | European Archives of Oto-Rhino-Laryngology2010，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员